Science Current Events | Science News | Brightsurf.com
 

Brain signal IDs responders to fast-acting antidepressant

August 07, 2012
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

The signal is among the latest of several such markers, including factors detectable in blood, genetic markers, and a sleep-specific brain wave, recently uncovered by the NIH team and grantee collaborators. They illuminate the workings of the agent, called ketamine, and may hold promise for more personalized treatment.

"These clues help focus the search for the molecular targets of a future generation of medications that will lift depression within hours instead of weeks," explained Carlos Zarate, M.D., of the NIH's National Institute of Mental Health (NIMH). "The more precisely we understand how this mechanism works, the more narrowly treatment can be targeted to achieve rapid antidepressant effects and avoid undesirable side effects."

Zarate, Brian Cornwell, Ph.D., and NIMH colleagues report on their brain imaging study online in the journal Biological Psychiatry.

Previous research had shown that ketamine can lift symptoms of depression within hours in many patients. But side effects hamper its use as a first-line medication. So researchers are studying its mechanism of action in hopes of developing a safer agent that works similarly.

Ketamine works through a different brain chemical system than conventional antidepressants. It initially blocks a protein on brain neurons, called the NMDA receptor, to which the chemical messenger glutamate binds. However, it is not known if the drug's rapid antidepressant effects are a direct result of this blockage or of downstream effects triggered by the blockage, as suggested by animal studies.

To tease apart ketamine's workings, the NIMH team imaged depressed patients' brain electrical activity with magnetoencephalography (MEG). They monitored spontaneous activity while subjects were at rest, and activity evoked by gentle stimulation of a finger, before and 6.5 hours after an infusion of ketamine.

It was known that by blocking NMDA receptors, ketamine causes an increase in spontaneous electrical signals, or waves, in a particular frequency range in the brain's cortex, or outer mantle. Hours after ketamine administration-in the timeframe in which ketamine relieves depression - spontaneous electrical activity in people at rest was the same whether or not the drug lifted their depression.

Electrical activity evoked by stimulating a finger, however, was different in the two groups. MEG imaging made it possible to monitor excitability of the somatosensory cortex, the part of the cortex that registers sensory stimulation. Those who responded to ketamine showed an increased response to the finger stimulation, a greater excitability of the neurons in this part of the cortex.

Such a change in excitability is likely to result, not from the immediate effects of blocking the receptor, but from other processes downstream, in the cascade of effects set in motion by NMDA blockade, say the researchers. Evidence points to changes in another type of glutamate receptor, the AMPA receptor, raising questions about whether the blocking of NMDA receptors is even necessary for ketamine's antidepressant effect. If NMDA blockade is just a trigger, then targeting AMPA receptors may prove a more direct way to effect a lifting of depression.

A separate study of ketamine biomarkers by the NIMH group adds to evidence that the drug may work, in part, by strengthening neural connections. Thirty treatment resistant depressed patients who received ketamine showed increased sleep-specific slow brainwave activity (SWA) - a marker of such strengthened synapses and of increased synchronization of networks in the cortex. They also had higher blood levels of a key neural growth chemical, brain-derived neurotrophic factor (BDNF), previously linked, in animal studies, to ketamine's action. Intriguingly, the boosts in BDNF were proportional to those in SWA only among 13 participants whose depressions significantly lifted - suggesting a potential marker of successful treatment.

"Linked SWA and BDNF may represent correlates of mood improvement following ketamine treatment," said Zarate. "These may be part of the mechanism underlying the rapid antidepressant effects and prove useful in testing potential new therapies that target the glutamate system."

The increases in SWA, detected via electroencephalography (EEG), were also reflected in increased slope and amplitude of individual brainwaves - additional indicators of neural health and adaptability.

Prior to discovery of ketamine's antidepressant effects, the only fast-acting antidepressant therapies were sleep deprivation and electroconvulsive therapy (ECT), both of which are also thought to work, at least in part, by stimulating BDNF.

There is also new evidence that people with one of two common versions of the gene that codes for BDNF respond better to ketamine - and clues about why. The versions are created by a site in the human BDNF gene where the genetic code differs slightly across individuals. Each person inherits two copies of the gene, one from each parent. So people can inherit one or two copies of each version.

In June, NIMH-funded researchers reported that ketamine's ability to spur the growth of neural connections and trigger antidepressant-like behavioral responses was impaired in mice genetically engineered to express two copies of a risk version of the human BDNF gene that is carried by about 30 percent of the population. NIMH grantees George Aghajanian M.D., and Ronald Duman, Ph.D., of Yale University, New Haven, Conn., also discovered atrophy in extensions of neurons and dampened electrical activity in key cells at the front of the brain, with the risk version.

The mouse results suggested that the same site of variability in the BDNF gene might similarly influence patients' responses to ketamine. In July, Zarate and NIMH colleagues reported that in 62 depressed patients, this variability in the BDNF gene accounted for 28 percent of difference in patients' responsiveness to the medication. As expected, the antidepressant effect was strongest in patients with two copies of the other, protective version, which is carried by about 60 percent of the population.

These results strengthen the case for BDNF's pivotal role in mediating antidepressant effects produced via the glutamate system. They also suggest that it might be possible to improve ketamine's antidepressant effect in risk version carriers by first giving them treatments known to enhance BDNF, such as exercise, transcranial magnetic stimulation, ECT, or conventional antidepressants.

In another recent study by the NIMH team and NIH collaborators, by-products of the chemical breakdown of ketamine, detectable in blood, helped to sort out responders from non-responders, as well as diagnosis and symptoms. This first study of its kind pinpointed correlates of such downstream ketamine metabolites in 45 treatment resistant depressed unipolar and 22 depressed bipolar patients.

Blood levels of one metabolite were higher among bipolar non-responders, indicating that these patients might require a lower dose of the drug for optimal efficacy. Levels of three related metabolites were higher in bipolar patients, with only one, of a different type, elevated in patients with major depression. Higher levels of three metabolites of the former type were also associated with lower scores on measures of psychotic and other side effects, following ketamine treatment. The identification of these downstream metabolites opens the door to possibly developing them into newer treatments that are better tolerated than ketamine.

Ketamine also recently produced the fastest, strongest and longest-lasting anti-suicidal intervention ever demonstrated in a controlled trial, according to Zarate and colleagues. In a replication of an earlier study, the researchers confirmed that ketamine not only lifts depression, but also reduces suicidal thoughts in bipolar patients. The effects were detectable as soon as 40 minutes after a single infusion in 15 treatment resistant patients taking mood stabilizers, and remained significant for at least a few days. Three fourths of the patients responded to ketamine, with none responding to a placebo. The results add reduced suicidal thinking to the list of potential therapeutic benefits of targeting the brain's glutamate system.

While the research on biological markers and mechanisms holds hope for development of more practical medications in the long term, questions remain about whether there might be a limited role for ketamine itself in the short term.

In a recent assessment of the state of the science, Zarate and American and European colleagues propose that intravenous ketamine may prove useful for acutely suicidal patients who receive treatment in hospital emergency rooms. It may also offer an alternative to ECT, long considered the treatment of last resort for treatment resistant depression, but fraught with concerns about cognitive side effects.

However, the researchers recommend against the use of ketamine outside of a hospital setting, citing potential cardiovascular and other risks. They note that anesthesiologists participate in the trials at NIMH and Mount Sinai School of Medicine, New York City which also require a 24-hour inpatient stay following drug infusion.

Among about 163 patients who have been studied to date, the drug has been well tolerated and seems a reasonable treatment option for most treatment resistant depressed patients, say the researchers. Studies are under way using nasally administered ketamine and other strategies to determine how the rapid antidepressant affect might best be sustained.

"We are investigating ketamine in multiple ways - studying genes, gene expression, synapses, cells, circuits, and symptoms with neuroimaging, genetics, electrophysiological measures and other techniques," explained Zarate. "These studies hold hope for predicting the likelihood of response and for gaining insights into mechanisms of action."

NIH/National Institute of Mental Health


Related Ketamine Current Events and Ketamine News Articles


Ketamine Can Be A Wonder Drug for ER Patients And Their Physicians
For critically ill patients arriving at the emergency department, the drug ketamine can safely provide analgesia, sedation and amnesia for rapid, life-saving intubation, despite decades-old studies that suggested it raised intracranial pressure.

NYU Researchers Find Prior Drug Use is the Greatest Predictor of Ecstasy Use Among U.S. High School Seniors
Ecstasy, also known by its chemical abbreviation MDMA, is an illicit drug that is commonly taken at nightclubs and dance parties. Ecstasy's street names include: "Molly" (U.S.), "Mandy" (U.K.), "E," and "X."

E-Cigarettes Far Less Harmful Than Cigarettes, says London School of Economics Researcher at INFORMS Decision/Analytics Conference
A London School of Economics researcher examining the public and private dangers of drugs argues against demonizing e-cigarettes in a presentation being given at a conference of the Institute for Operations Research and the Management Sciences (INFORMS).

Researchers identify new compound to treat depression
There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug.

Researchers uncover new insights into developing rapid-acting antidepressant for treatment-resistant depression
UT Southwestern Medical Center researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression.

Intranasal ketamine confers rapid antidepressant effect in depression
A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder.

Drug residues in Swedish sewage water
Chemists at Umeå University have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations.

mTOR: A key brain signaling mechanism for rapidly acting antidepressants
Two years ago, mammalian target of rapamycin or mTOR, a signaling protein, was identified as a key mediator of the antidepressant effects of ketamine, the first rapidly acting antidepressant medication to be identified.

Would an 'anti-ketamine' also treat depression?
Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments.

A potential new class of fast-acting antidepressant
More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms.
More Ketamine Current Events and Ketamine News Articles

Ketamine: Dreams and Realities

Ketamine: Dreams and Realities
by Karl Jansen (Author)


Ketamine: Dreams and Realities is a non-biased and comprehensive overview of the drug ketamine. It covers everything from its recreational use in the dance community, its use as an adjunct to psychotherapy as an aid in overcoming chemical dependency and alcoholism, to the types of mystical experiences induced by ketamine. This book includes information on the possible benfits and dangers of ketamine use along with an authoratative treatment plan for individuals who become addicted to the drug. It is wealth of information for both laypersons and medical professionals alike.

The Little Book of Ketamine (Little Book Series)

The Little Book of Ketamine (Little Book Series)
by Kit Kelly (Author)


Used worldwide as both an anesthetic and a recreational psychedelic drug, ketamine has recently attracted the attention of medical researchers, law enforcement officers, and people interested in exploring alternative spirituality and consciousness. The book describes the drug's history, its use in the underground party scene, and its sought-after effects as well as its dangers and how to reduce them.

How to Fuck Up Everything and Die Alone: The JRJ Drug Sampler

How to Fuck Up Everything and Die Alone: The JRJ Drug Sampler
by Swallowdown Press


"This is entertainment...and literature."--JACK KETCHUM

"A dazzling writer. Seriously amazing short stories."--CHUCK PALAHNIUK

"The guy's a genius. Reminds me of William Gibson--the dark interest in altered states of consciousness, the unrelentingly furious forward movement, the same kind of unlimited imagination."--BEN LOORY

This volume of the JRJ Sampler Series contains three stories of drug-fueled madness, self-surgery, and all-night parties gone apocalyptic: "A Number of Things Come to Mind" "Dissociative Skills""Liquidation"

Ketamine: Dangerous Hallucinogen (Drug Abuse & Society: Cost to a Nation)

Ketamine: Dangerous Hallucinogen (Drug Abuse & Society: Cost to a Nation)
by Brad Lockwood (Author)


Read the facts and history of the drug while recounting one teenager?s true story of ketamine addiction and recovery. Learn how the body reacts to ketamine, its potential side effects and the treatment options for both casual users and those few who become full-blown addicts. Comprehensive resources including organizations and help/hotlines are presented within the appendix of each title.

The Scientist: A Metaphysical Autobiography

The Scientist: A Metaphysical Autobiography
by John C. Lilly (Author)


Tells the story of John Lilly's discoveries from his early experiments; mapping the brains of monkeys and communication with dolphins, to his experience with consciousness expanding drugs. The book includes an update on Lilly's work on human/dolphin communication and returning animals to the wild.

The Ketamine Sun, Part 2: A Slow-breathing, Slumped-over Queen Poisoned by an Asp Spitting Hydrochloride

The Ketamine Sun, Part 2: A Slow-breathing, Slumped-over Queen Poisoned by an Asp Spitting Hydrochloride
by Tar Hole Dimedrop


In this second installment of Cole Coonce‘s LA punk noir novel "The Ketamine Sun," studio detective Blackie Carbon has been hired by a Japanese business magnate to clean up his tawdry daughter’s sordid web of designer drugs and amateur adult films under the nom de smut "Cremora Creamer." Carbon finds Cremora's sex tape and tracks down her pornographer, only to walk into a grisly crime scene when searching for the original copies.

This installment is the gritty follow-up to the initial offering, "The Ketamine Sun, Part 1: Cremora Creamer, The Betamax Malaprop and A Newtonian Bang," which is also available at the Amazon Kindle store.

The Ketamine Sun, Part 1: Cremora Creamer, The Betamax Malaprop and A Newtonian Bang

The Ketamine Sun, Part 1: Cremora Creamer, The Betamax Malaprop and A Newtonian Bang
by Tar Hole Dimedrop


Aging LA punk rocker and now-studio detective Blackie Carbon is working for the wealthy Kamiokande family. Toshiro Kamiokande, crippled by a failing Japanese electronics corporation and movie studio, is being squeezed by an Internet pornographer and he wants Carbon to calm down the situation. But with Kamiokande's two wild, untamable daughters prowling and probing LA's nether regions, Carbon's grabbed a couple of tawdry tigers by the tail—and that's before the shooting starts.

Doomed

Doomed
by Chuck Palahniuk (Author)


Welcome to Purgatory. Chuck Palahniuk style. 

After a botched Halloween ritual, Madison Spencer, the snarkiest dead girl in the universe, finds herself trapped in Purgatory, otherwise known as Earth. The upside: she is no longer subject to physical limitations (she can pass through doors and walls). The downside: well, she's still dead. Her first stop is her parents' luxurious apartment, where she encounters her grandmother ghost. For Madison, the encounter triggers memories of the awful summer she spent upstate. As she revisits the painful truth of what transpired over those months, her saga of eternal damnation takes on a new and sinister meaning. It turns out, Madison and her parents have always been key elements of Satan's master plan—doomsday. 


Buzzed: The Straight Facts About the Most Used and Abused Drugs from Alcohol to Ecstasy (Fully Revised and Updated Fourth Edition)

Buzzed: The Straight Facts About the Most Used and Abused Drugs from Alcohol to Ecstasy (Fully Revised and Updated Fourth Edition)
by Cynthia Kuhn (Author), Scott Swartzwelder (Author), Wilkie Wilson (Author), Jeremy Foster (Foreword), Leigh Heather Wilson (Foreword)


The fourth edition of the essential, accessible source for understanding how drugs work and their effects on body and behavior. A bestseller in its three previous editions, Buzzed is now revised and updated with the most recent discoveries about drugs. It includes new information about biological and behavioral changes in addiction, the prescription-drug abuse epidemic, distinctive drug effects on the adolescent brain, and trends from synthetic cannabinoids to e-cigarettes. “Lively, highly informative, unbiased, [and] thorough” (Addiction Research & Theory), this no-nonsense handbook surveys the most used and abused drugs from caffeine to heroin to methamphetamine. In both quick-reference summaries and in-depth analysis, it reports on how these drugs enter the body, how they...

  The party's over: teens are drawn to club drugs like GHB, ecstasy, and ketamine. But the drugs are extremely dangerous. Kylene Beard found that out ... abuse): An article from: Scholastic Choices
by Denise Rinaldo (Author)


This digital document is an article from Scholastic Choices, published by Scholastic, Inc. on January 1, 2004. The length of the article is 2888 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: The party's over: teens are drawn to club drugs like GHB, ecstasy, and ketamine. But the drugs are extremely dangerous. Kylene Beard found that out when she almost died after taking GHB.(substance abuse)
Author: Denise Rinaldo
Publication: Scholastic Choices (Magazine/Journal)
Date: January 1, 2004
Publisher: Scholastic, Inc.
Volume: 19 Issue: 4 Page:...

© 2014 BrightSurf.com